Consensus Passage Bio, Inc.

Equities

PASG

US7027121000

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
1.22 ^USD	-1.61%		+1.67%	+20.79%

Mar. 04	Passage Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 04	Passage Bio, Inc. Appoints Kathleen Borthwick as Chief Financial Officer	CI

Evolution of the average Target Price on Passage Bio, Inc.

Price target over the last 5 years

History of analyst recommendation changes

3d388d6cc6b928951cf5890d73f9.O5CEQHhki4xsA2mDg4uNBQcNRiQ4sDf11QQxQh-1NoA.WePic0Ex1McLTBm1sdygcl56ImxP6QGTv0kHE1f4TLJ55dYNMyfg719UCg~f26d4e2716f2b925510c0e6acdd9d435

Analyst Recommendations on Passage Bio, Inc.

Wedbush Lowers Passage Bio's Price Target to $3 From $5, Maintains Outperform Rating	Nov. 13	MT
Chardan Trims Price Target on Passage Bio to $9 From $11, Keeps Buy Rating	23-08-08	MT
Raymond James Trims Price Target on Passage Bio to $9 From $10, Keeps Outperform Rating	23-05-12	MT
Chardan Cuts Price Target on Passage Bio to $11 From $18, Keeps Buy Rating	22-12-15	MT
Citigroup Adjusts Price Target on Passage Bio to $5 From $7, Maintains Buy Rating	22-11-11	MT
Guggenheim Adjusts Price Target on Passage Bio to $11 From $13, Maintains Buy Rating	22-11-11	MT
Wedbush Trims Passage Bio's Price Target to $5 From $6, Keeps Outperform Rating	22-11-11	MT
Canaccord Genuity Starts Passage Bio at Buy With $8 Price Target	22-11-08	MT
Chardan Research Lowers Passage Bio's Price Target to $18 From $34, Maintains Buy Rating	22-08-05	MT
Wedbush Adjusts Passage Bio Price Target to $6 From $9, Maintains Outperform Rating	22-08-04	MT
Goldman Sachs Adjusts Price Target for Passage Bio to $2 From $4, Maintains Neutral Rating	22-05-17	MT
Raymond James Adjusts Passage Bio's Price Target to $10 from $24, Keeps Outperform Rating	22-05-17	MT
Wedbush Cuts Passage Bio's Price Target to $9 From $16, Citing PBKR03 Update, PBFT02 Timeline; Outperform Rating Kept	22-05-17	MT
Citigroup Adjusts Price Target on Passage Bio to $10 From $15, Reiterates Buy Rating	22-05-17	MT
Chardan Research Adjusts Passage Bio's Price Target to $34 From $43; Buy Rating Kept	22-03-11	MT
JPMorgan Downgrades Passage Bio to Neutral From Overweight	22-03-08	MT
Raymond James Adjusts Passage Bio's Price Target to $24 From $29, Keeps Outperform Rating	22-03-04	MT
Goldman Sachs Analyst Starts Passage Bio at Neutral, Down From Buy, Sets $6 Price Target	22-01-19	MT
BTIG Adjusts Passage Bio's Price Target to $16 From $25, Reiterates Buy Rating	22-01-18	MT
Chardan Adjusts Price Target on Passage Bio to $43 From $45, Maintains Buy Rating	21-11-05	MT
Wedbush Adjusts Passage Bio PT to $23 From $25, Maintains Outperform Rating	21-11-04	MT
PASSAGE BIO : Wedbush Trims Price Target for Passage Bio to $25 From $26, Maintains Outperform	21-08-05	MT
PASSAGE BIO : Raymond James Starts Passage Bio at Outperform With $29 Price Target	21-07-01	MT
PASSAGE BIO : BTIG Starts Passage Bio at Buy With $25 Price Target	21-06-15	MT
PASSAGE BIO : Chardan Adjusts Price Target on Passage Bio to $45 From $35.50 on 3 Drug Trial OKs, Maintains Buy Rating	21-03-08	MT